{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:58:29Z","timestamp":1790125109304,"version":"4.0.1"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Whether there is difference in kidney disease risk between chronic hepatitis C virus (HCV) infection and resolved HCV infection remains inconclusive. Additionally, the impact of different HCV genotypes on kidney disease risk is relatively unknown. Accordingly, we conducted a population-based cross-sectional study to investigate the association of HCV infection status and genotype on kidney disease risk.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The study population were adult participants of 1999\u20132018 National Health and Nutrition Examination Survey in the United States. Chronic and resolved infection were defined as HCV seropositivity with and without detectable HCV RNA, respectively. HCV genotypes were classified into genotype 1, genotype 2, and other genotypes. Prevalent estimated glomerular filtration rate &lt; 60 ml\/min\/1.73 m<jats:sup>2<\/jats:sup> or urinary albumin creatinine ratio \u2265 30 mg\/g was defined as kidney disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The average age of study population (n = 44,998) was 46.7\u00b117.0 years with 49.8% being males. Compared with individuals without HCV infection (n = 44,157), those with resolved (n = 255) or chronic HCV infection (n = 586) had higher prevalence of kidney disease: 14.8%, 23.5%, and 20.1%, respectively (<jats:italic>p<\/jats:italic>&lt;0.001). After adjusting for potential confounders, we found that both resolved (adjusted OR: 1.40, 95% CI: 1.02\u20131.93) and chronic HCV infection (adjusted OR: 1.26, 95% CI: 1.01\u20131.57) correlated to increased kidney disease risk compared with no HCV infection. Additionally, individuals with HCV genotype 1 (adjusted OR: 1.41, 95% CI: 1.09\u20131.82) but not genotype 2 or other genotypes had greater kidney disease risk compared with no HCV infection. Furthermore, we observed that genotype 1 had 2-fold higher kidney disease risk (adjusted OR: 2.20, 95% CI: 1.07\u20134.53) compared with non-genotype 1 HCV infection.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Both resolved and chronic HCV infection, particularly genotype 1, were associated with higher kidney disease risk.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0271197","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T17:33:31Z","timestamp":1657301611000},"page":"e0271197","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of hepatitis C virus infection status and genotype with kidney disease risk: A population-based cross-sectional study"],"prefix":"10.1371","volume":"17","author":[{"given":"Yi-Chia","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-3131","authenticated-orcid":true,"given":"Ming-Yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"issue":"11","key":"pone.0271197.ref001","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMra2033539","article-title":"Extrahepatic Manifestations of Chronic HCV Infection","volume":"384","author":"P Cacoub","year":"2021","journal-title":"The New England journal of medicine"},{"issue":"1","key":"pone.0271197.ref002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2010.01.015","article-title":"Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study","volume":"56","author":"JJ Lee","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"pone.0271197.ref003","doi-asserted-by":"crossref","first-page":"17197","DOI":"10.1038\/s41598-021-96782-x","article-title":"Renal function trajectories in hepatitis C infection: differences between renal healthy and chronic kidney disease individuals","volume":"11","author":"C-K Hsu","year":"2021","journal-title":"Scientific reports"},{"issue":"5","key":"pone.0271197.ref004","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","author":"MZ Molnar","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"10","key":"pone.0271197.ref005","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2215\/CJN.01530218","article-title":"Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection","volume":"13","author":"SY Tartof","year":"2018","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"issue":"6","key":"pone.0271197.ref006","doi-asserted-by":"crossref","first-page":"e100790","DOI":"10.1371\/journal.pone.0100790","article-title":"Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis","volume":"9","author":"J-J Lee","year":"2014","journal-title":"PloS one"},{"issue":"1","key":"pone.0271197.ref007","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cgh.2009.08.031","article-title":"Lack of association between hepatitis C infection and chronic kidney disease","volume":"8","author":"SK Asrani","year":"2010","journal-title":"Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association"},{"issue":"5","key":"pone.0271197.ref008","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/cts.12321","article-title":"Association of Hepatitis C Virus Infection with Proteinuria and Glomerular Filtration Rate","volume":"8","author":"N Kurbanova","year":"2015","journal-title":"Clinical and translational science"},{"issue":"4","key":"pone.0271197.ref009","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2215\/CJN.06920711","article-title":"Hepatitis C virus infection and kidney disease: a meta-analysis","volume":"7","author":"F Fabrizi","year":"2012","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"1","key":"pone.0271197.ref010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.kint.2019.04.030","article-title":"Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease","volume":"97","author":"ME Sise","year":"2020","journal-title":"Kidney international"},{"issue":"2","key":"pone.0271197.ref011","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.29505","article-title":"Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD","volume":"67","author":"H Park","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"pone.0271197.ref012","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"The lancet Gastroenterology & hepatology"},{"issue":"7","key":"pone.0271197.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0040245","article-title":"Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults","volume":"7","author":"A Mocroft","year":"2012","journal-title":"PLoS ONE"},{"issue":"15","key":"pone.0271197.ref014","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/QAD.0b013e3283574e71","article-title":"Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients","volume":"26","author":"L Peters","year":"2012","journal-title":"AIDS (London, England)"},{"issue":"3","key":"pone.0271197.ref015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.kint.2017.03.021","article-title":"High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease","volume":"92","author":"T-S Lai","year":"2017","journal-title":"Kidney international"},{"issue":"3","key":"pone.0271197.ref016","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/hep.29192","article-title":"Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study","volume":"66","author":"T-S Lai","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"56","key":"pone.0271197.ref017","first-page":"1","article-title":"National health and nutrition examination survey: plan and operations, 1999\u20132010","author":"G Zipf","year":"2013","journal-title":"Vital and health statistics Ser 1, Programs and collection procedures"},{"issue":"18","key":"pone.0271197.ref018","first-page":"362","article-title":"Testing for HCV infection: an update of guidance for clinicians and laboratorians","volume":"62","year":"2013","journal-title":"MMWR Morbidity and mortality weekly report"},{"issue":"4","key":"pone.0271197.ref019","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1053\/j.ajkd.2009.12.016","article-title":"Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"55","author":"K Matsushita","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"pone.0271197.ref020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jhep.2019.11.014","article-title":"Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals","volume":"72","author":"C-H Liu","year":"2020","journal-title":"Journal of hepatology"},{"issue":"2","key":"pone.0271197.ref021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12072-018-9859-9","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment","volume":"12","author":"T Okubo","year":"2018","journal-title":"Hepatology international"},{"issue":"6","key":"pone.0271197.ref022","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"V Saxena","year":"2016","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"issue":"3","key":"pone.0271197.ref023","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s10620-015-3918-z","article-title":"Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES","volume":"61","author":"SS Rogal","year":"2016","journal-title":"Digestive diseases and sciences"},{"issue":"4","key":"pone.0271197.ref024","doi-asserted-by":"crossref","first-page":"e0231102","DOI":"10.1371\/journal.pone.0231102","article-title":"Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment","volume":"15","author":"S-M Chiu","year":"2020","journal-title":"PloS one"},{"issue":"22","key":"pone.0271197.ref025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000020436","article-title":"Direct acting antiviral HCV treatment does not influence renal function","volume":"99","author":"M Driedger","year":"2020","journal-title":"Medicine"},{"key":"pone.0271197.ref026","article-title":"Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection","author":"C-H Liu","year":"2022","journal-title":"Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association"},{"issue":"6","key":"pone.0271197.ref027","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jhep.2019.07.021","article-title":"Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations","volume":"71","author":"C Rossi","year":"2019","journal-title":"Journal of hepatology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0271197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T17:34:12Z","timestamp":1657301652000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0271197"}},"subtitle":[],"editor":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0271197","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]}}}